CDT Equity Inc. (CDT )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CDT
- Company CDT Equity Inc.
- Price $0.68
- Changes Percentage -5.02
- Change -0.04
- Day Low $0.63
- Day High $0.71
- Year High $168
- Year Low $0.63
- Market Cap $921,017
- Price Avg 50 EMA (D) $1.36
- Price Avg 200 EMA (D) $10.95
- Exchange NASDAQ
- Volume 225,971
- Average Volume 781,003
- Open $0.71
- Previous Close $0.72
- EPS -179.34
- PE 0.00
- Earnings Announcement 2026-03-27 04:00:00
- Shares Outstanding $1,352,448
Company brief: CDT EQUITY INC. (CDT )
- Healthcare
- Biotechnology
- Dr. David Joszef Tapolczay
- https://www.conduitpharma.com
- US
- N/A
- 03-28-2022
- US20678X1063
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
CDT Corporation News
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
globenewswire.com -- NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarbor...